We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR)oral small molecule drug discovery powered by our proprietary Native Complex Platform™. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.
